TD Cowen Maintains Buy on Jazz Pharmaceuticals, Raises Price Target to $275
Jazz Pharmaceuticals Public Limited Company
Jazz Pharmaceuticals Public Limited Company JAZZ | 0.00 |
TD Cowen analyst Joseph Thome maintains Jazz Pharmaceuticals (NASDAQ:
JAZZ) with a Buy and raises the price target from $220 to $275.